chronic hepatitis, cirrhosis, fibrosis, inactive carrier, phases of infection.
Abstract :
[en] Introduction : Nationwide studies are mandatory to assess
changes in the epidemiology of HBV infection in Europe.
Aim : To describe epidemiological characteristics of HBsAgpositive
patients, especially inactive carriers, and to evaluate how
practitioners manage HBV patients in real life.
Methods : Belgian physicians were asked to report all chronically
infected HBV patients during a one-year period.
Results : Among 1,456 patients included, 1,035 (71%) were
classified into one of four phases of chronic infection : immune
tolerance (n = 10), HBeAg-positive hepatitis (n = 248), HBeAgnegative
hepatitis (n = 420) and inactive carrier state (n = 357
HBeAg-negative patients with ALT < upper limit of normal (ULN)
and HBV DNA < 2,000 IU/mL). Using less restrictive criteria for
ALT (1-2 ULN) or HBV DNA (2,000-20,000 IU/mL), 93 unclassified
patients were added to the group of inactive carriers. These 93
additional inactive carriers were younger, more frequently males,
with similar risk factors for HBV infection and histological features
compared to inactive carriers according to recent guidelines.
Recent guidelines on management of HBV patients were generally
followed, but systematic HBV DNA measurements and HDV coinfection
screening should be reinforced.
Conclusion : In Belgium, an inactive carrier state was a common
form of chronic HBV infection. Using less restrictive criteria for
classification of inactive carriers did not modify their main characteristics
and seemed better adapted to clinical practice. Recent
guidelines on management of HBV patients should be reinforced.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Deltenre, P.
Laleman, W.
Van Gossum, M.
Lenaerts, A.
Colle, I.
Michielsen, P.
Adler, M.
DELWAIDE, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
CADRANEL J.F., LAHMEK P., CAUSSE X., BELLAICHE G., BETTAN L., FONTANGES T. et al. Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis-results of a nationwide survey. Aliment. Pharmacol. Ther., 2007, 26: 565-576.
FATTOVICH G., BORTOLOTTI F., DONATO F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol., 2008, 48: 335-352.
ROTMAN Y., BROWN T.A., HOOFNAGLE J.H. Evaluation of the patient with hepatitis B. Hepatology, 2009, 49: S22-27.
CHU C.J., HUSSAIN M., LOK A.S. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology, 2002, 36: 1408-1415.
CHU C.J., LOK A.S. Clinical utility in quantifying serum HBV DNA levels using PCR assays. J. Hepatol., 2002, 36: 549-551.
YUEN M.F., YUAN H.J., WONG D.K., YUEN J.C., WONG W.M., CHAN A.O., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut, 2005, 54: 1610-1614.
LIN C.L., LIAO L.Y., LIU C.J., YU M.W., CHEN P.J., LAI M.Y. et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology, 2007, 45: 1193-1198.
CHU C.M., CHEN Y.C., TAI D.I., LIAW Y.F. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin. Gastroenterol. Hepatol., 2010, 8: 535-540.
KIM H.C., NAM C.M., JEE S.H., HAN K.H., OH D.K., SUH I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ, 2004, 328: 983.
KUMAR M., SARIN S.K., HISSAR S., PANDE C., SAKHUJA P., SHARMA B.C. et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastro - enterology, 2008, 134: 1376-1384.
PITON A., POYNARD T., IMBERT-BISMUT F., KHALIL L., DELATTRE J., PELISSIER E. et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology, 1998, 27: 1213-1219.
BEUTELS M., VAN DAMME P., AELVOET W., DESMYTER J., DONDEYNE F., GOILAV C. et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur. J. Epidemiol., 1997, 13: 275-280.
QUOILIN S., HUTSE V., VANDENBERGHE H., CLAEYS F., VERHAEGEN E., DE COCK L. et al. A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. Eur. J. Epidemiol., 2007, 22: 195-202.
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology, 1994, 20: 15-20.
BEDOSSA P., POYNARD T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 1996, 24: 289-293.
STEFOS A., GATSELIS N., ZACHOU K., RIGOPOULOU E., HADJICHRISTODOULOU C., Dalekos G.N. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. Eur. J. Intern. Med., 2009, 20: 35-43.
HADZIYANNIS S.J., VASSILOPOULOS D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology, 2001, 34: 617-624.
BRUNETTO M.R., OLIVERI F., COCO B., LEANDRO G., COLOMBATTO P., GORIN J.M. et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J. Hepatol., 2002, 36: 263-270.
ZARSKI J.P., MARCELLIN P., LEROY V., TREPO C., SAMUEL D., GANNE-CARRIE N. et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J. Hepatol., 2006, 45: 355-360.
HADZIYANNIS S.J., PAPATHEODORIDIS G.V. Hepatitis B e antigennegative chronic hepatitis B: natural history and treatment. Semin. Liver Dis., 2006, 26: 130-141.
MANESIS E.K. HBeAg-negative chronic hepatitis B: from obscurity to prominence. J. Hepatol., 2006, 45: 343-346.
RAPTOPOULOU M., PAPATHEODORIDIS G., ANTONIOU A., KETIKOGLOU J., TZOURMAKLIOTIS D, VASILIADIS T. et al. Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B: a multicentre Greek study. J. Viral Hepat., 2009, 16: 195-202.
ZACHARAKIS G., KOSKINAS J., KOTSIOU S., TZARA F., VAFEIADIS N., PAPOUTSELIS M. et al. The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J. Hepatol., 2008, 49: 884-891.
PAPATHEODORIDIS G.V., MANESIS E.K., MANOLAKOPOULOS S., ELEFSINIOTIS I.S., GOULIS J., GIANNOUSIS J. et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology, 2008, 48: 1451-1459.
YIM H.J., LOK A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. H epatology, 2006, 43: S173-181.
MANNO M., CAMMA C., SCHEPIS F., BASSI F., GELMINI R., GIANNINI F. et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology, 2004, 127: 756-763.
VILLA E., FATTOVICH G., MAURO A., PASINO M. Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis. Dig. Liver. Dis., 2011, 43, Suppl 1: S8-S14.
Liver EAFTSOT. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol., 2009, 50: 227-242.